Mitochondrial electron transport is the cellular target of the oncology drug elesclomol

Area of Science:

• Biochemistry
• Cell Biology
• Cancer Therapeutics

Background:

• Elesclomol is an investigational drug with potent antitumor activity, attributed to elevated reactive oxygen species (ROS) and oxidative stress.
• The precise molecular targets and mechanism of action for elesclomol-induced ROS generation and cell death remained undefined.
• Yeast (Saccharomyces cerevisiae) exhibits similar cellular responses to elesclomol as cancer cells, suggesting conserved mechanisms.

Purpose of the Study:

• To elucidate the molecular target(s) and mechanism of action of elesclomol in generating ROS and inducing cell death.
• To leverage yeast genetics to understand drug-induced disruptions in cellular processes.
• To validate the findings in human cancer cells, specifically melanoma.

Main Methods:

• Utilized a yeast-based technology to investigate the mechanism of action and cellular targets of elesclomol.
• Examined the interaction of elesclomol with cellular processes, focusing on mitochondrial function.
• Conducted experiments in melanoma cells, including drug treatments and studies on cells with impaired electron transport chain (ETC) function.

Main Results:

• Elesclomol does not target a specific cellular protein; instead, it disrupts a coherent set of mitochondrial processes.
• The drug's redox chemistry drives interaction with the electron transport chain (ETC), leading to high ROS generation within mitochondria.
• This mechanism of ROS generation and subsequent cell death was confirmed in human melanoma cells.

Conclusions:

• Elesclomol's mode of action involves targeting mitochondrial electron transport chain (ETC) function to induce oxidative stress and cancer cell death.
• This detailed understanding provides a mechanistic basis for elesclomol's therapeutic effects.
• The findings support the potential for biomarker-based patient stratification in clinical settings.